Amgen posts 24% profit growth despite Aranesp drag
This article was originally published in Scrip
Executive Summary
Amgen's profits crept up as lower costs and taxes helped contain a double-digit decline of sales of its anaemia drug Aranesp (darbepoetin alfa). Third-quarter earnings rose by 24% to $1.4 billion and the company confirmed that full-year revenues will be towards the top end of its forecast.